CalciMedica Inc. (NASDAQ:CALC) Short Interest Update

CalciMedica Inc. (NASDAQ:CALC) saw a large decline in short interest in July. As of July 15th, there was short interest totaling 960,731 shares, a decline of 41.8% from the June 30th total of 1,651,945 shares. Based on an average trading volume of 406,881 shares, the short-interest ratio is currently 2.4 days. Approximately 10.4% of the company’s stock are sold short.

Insider Activity at CalciMedica

In other news, Director Fred A. Middleton acquired 248,972 shares of CalciMedica stock in a transaction dated Thursday, June 25th. The shares were acquired at an average cost of $0.80 per share, for a total transaction of $199,177.60. Following the acquisition, the director owned 1,063,272 shares of the company’s stock, valued at $850,617.60. This trade represents a 30.57% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 28.25% of the company’s stock.

Institutional Investors Weigh In On CalciMedica

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CALC. 180 Wealth Advisors LLC boosted its stake in shares of CalciMedica by 297.2% during the first quarter. 180 Wealth Advisors LLC now owns 126,500 shares of the company’s stock worth $68,000 after buying an additional 94,650 shares during the period. Boothbay Fund Management LLC acquired a new stake in CalciMedica during the 4th quarter worth approximately $506,000. PVG Asset Management Corp acquired a new stake in CalciMedica during the 4th quarter worth approximately $302,000. Renaissance Technologies LLC grew its stake in shares of CalciMedica by 45.0% in the 1st quarter. Renaissance Technologies LLC now owns 128,075 shares of the company’s stock valued at $69,000 after purchasing an additional 39,775 shares during the last quarter. Finally, Envestnet Asset Management Inc. grew its stake in shares of CalciMedica by 58.2% in the 2nd quarter. Envestnet Asset Management Inc. now owns 93,433 shares of the company’s stock valued at $149,000 after purchasing an additional 34,386 shares during the last quarter.

CalciMedica Stock Up 5.2%

CALC traded up $0.04 on Friday, reaching $0.88. The company had a trading volume of 132,163 shares, compared to its average volume of 1,107,646. CalciMedica has a 1 year low of $0.46 and a 1 year high of $7.20. The stock has a market capitalization of $13.97 million, a PE ratio of -0.67 and a beta of 0.89. The stock has a 50-day moving average price of $0.82 and a 200-day moving average price of $1.11.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. HC Wainwright restated a “neutral” rating on shares of CalciMedica in a research note on Wednesday. Weiss Ratings raised CalciMedica from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $10.00.

CalciMedica Company Profile

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.